ABSTRACT
Dissociation of graft-versus-leukemia (GvL). effects from graft-versus-host disease (GvHD) is the ultimate goal of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of hematological malignancies. The pivotal role of donor T cells in both anti-leukemic and anti-host reactivity of allogeneic stem cell grafts has been known since the first transplants for fatal leukemia were performed over 25 years ago. Growing understanding of the T cell-mediated GvL response has revealed the importance of host-type antigenpresenting cells and the capacity of adoptively transferred donor T cells in inducing anti-leukemic responses, and has led to a re-evaluation of the relative roles of the pretransplant conditioning regimen and the allogeneic stem cell graft. Key advances in clinical practice such as reduced-intensity stem cell transplantation and donor lymphocyte infusions are now routinely applied and allow for the induction of potent antileukemic effects, while GvHD can to some extent be controlled. Other strategies to separate T cell-mediated antileukemic effects from GvHD are antigen-specific adoptive T cell-therapy and recipient lymphocyte infusion (RLI) and these are in an experimental stage. Importantly, a role for alloreactive natural killer cells in mediating GvL without GvHD has emerged in patient studies of MHC haplotype-mismatched alloHSCT. Finally, experimental studies indicate that naturally occurring regulatory T cells may differentially affect GvHD and GvL.
HISTORICAL PERSPECTIVE: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-TATION AND THE GRAFT-VERSUS-LEUKEMIA EFFECT
Allogeneic hematopoietic stem cell transplanttation (alloHSCT) currently is a cornerstone in the treatment of hematological malignancies. Depending on the nature of the malignancy and the stage of the disease, alloHSCT can induce durable remission in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML), myelodysplasia (MDS) and high-risk lymphoma. Since the first bone marrow transplantation (BMT) was performed for fatal leukemia over 25 years ago, the practice of alloHSCT has evolved considerably, and the paradigm has shifted from alloHSCT as a means to rescue the patients' immunohematopoietic system following high-dose chemo-and/or radiotherapy, to a potent form of antileukemic immunotherapy.
In 1956 Barnes et al. (1) , exploring X-ray irradiation plus BMT as a therapeutic regimen for transplantable leukemia in mice, first demonstrated superiority of alloBMT to syngeneic BMT in achieving successful eradication of leukemia. In 1965, Mathé et al. (2) described the first case of an irradiated leukemia patient exhibiting successful engraftment of allogeneic bone marrow (alloBM) with prolonged leukemia-free survival, suggesting that the allogeneic transplant exerted an antileukemic effect superimposed on that of radiotherapy. At that time it had become clear that immune reactivity of the donor graft against host tissues generates GvHD (3) . Another decade later, Odom et al. (4) used the term 'graft-versus-leukemia reaction' when they described the case of an alloBMT patient showing remission of relapsed leukemia coincident with a graft-versus-host reaction, and in 1981, Weiden et al. (5) published a retrospective study revealing an association between post-transplant GvHD and reduced leukemia relapse rates, supporting Odom's hypothesis that the alloBM graft can confer an immune-mediated anti-tumor effect. Horowitz et al. (6) further substantiated the relationship between GvHD, in particular the extent of histoincompatibility and the role of donor T cells, and antileukemic immune reactivity of the alloBM graft. These authors (6) observed that leukemia relapse rates were reduced when alloBMT gave rise to both acute and chronic GvHD, as opposed to when it led to chronic GvHD only. Moreover, relapse rates in recipients of T cell-depleted BM grafts were higher than those in non-T cell-depleted BMT patients, but lower than those in recipients of twin transplants.
Since these early studies, GvHD remains the principal complication of alloHSCT, leading to considerable morbidity and mortality. Effective measures to prevent GvHD, such as HLA matching, T cell depletion or post-transplant immunosuppression have the undesired consequence of mitigating leukemia-free survival and today it is well established that the curative potential of alloHSCT for leukemia critically depends on the GvL effect. This concept has led investigators to test the post-transplant infusion of donor lymphocytes (donor lymphocyte infusions, DLI), in mice and subsequently in humans in the mid 1990s (7) , as a means to induce or potentiate antileukemic reactivity in the post-transplant period (8) . Although success rates of DLI varied amongst different types of leukemia, its curative potential has supported its introduction into clinical practice (7) .
The studies, showing that the benefit of alloHSCT derives not so much from its ability to reconstitute the hematopoietic system, but rather from its specific anti-leukemic potential, led to the idea to tone down the highly toxic conditioning component and to maximally exploit the alloreactivity of the stem cell graft, in reduced intensity stem cell transplantation (RIST) strategies (Box 1) (9) (10) (11) . The first experience with socalled non-myeloablative conditioning (Box 1) in alloHSCT procedures was reported on by Slavin and colleagues in 1998 (12) . Today, these regimens have proved to be clinically effective (13), and to allow for older and more advanced leukemic patients to undergo alloHSCT (14) . Although these key advances have improved the outcome of alloHSCT procedures for leukemias, considerable risks for post-transplant morbidity, including disease relapse continue to exist. Furthermore, the immune mechanisms underlying the GvL effect, in particular those which would allow its dissociation from GvHD, are still incompletely understood. Moreover, as post-transplantation immunosuppressive therapy is often necessary to control GvHD, the GvL effect may rarely be expected to be complete. Since the early days of alloHSCT practice it has been clear that GvL is closely associated with GvHD. Nevertheless, there is now ample experimental and clinical evidence to indicate that, apart from donor T cells, donor Natural Killer (NK) cells can contribute significantly to GvL, and that GvL and GvHD can be separated. Here, we review the immunological mechanisms underlying the GvL reaction after alloHSCT and present the currently available experimental and clinical evidence indicating that GvL can be dissociated from GvHD.
IMMUNOBIOLOGY OF GRAFT-VERSUS-HOST DISEASE AND THE GRAFT-VERSUS-LEUKEMIA EFFECT

Graft-versus-host disease
GvHD is the cause of considerable posttransplant morbidity and mortality, and therefore is the most important obstacle to the overall success of alloHSCT (15, 16) . According to literature, the incidence of acute GvHD ranges from 16 to 64 %, depending on the type of patient and alloHSCT procedure (17) (18) (19) (20) (21) (22) (23) (24) . Chronic GvHD occurs in 40 to 60% of long-term survivors of alloHSCT, and this rate is expected to still increase in the future because of the increasing age of the patient population eligible for alloHSCT, the increasing use of peripheral blood as a stem cell source, the application of DLI, and the enlistment of mismatched and unrelated donors (15) .
As early as 1966, Billingham stated that acute GvHD develops on the condition that the transplanted graft Box 1: Reduced Intensity Stem Cell Transplantation.Throughout this review, the terms reduced-intensity stem cell transplantation (rist). and nonmyeloablative conditioning are used to refer to any transplant protocol involving a conditioning regimen that was intented not to be myeloablative. In literature, the terms 'reduced intensity conditioning', 'nonmyeloablative conditioning', 'mini-transplant', 'minimal intensity stem cell transplantation' and 'moderate intensity stem cell transplantation' are used. Although they are used often interchangeably, in general these terms refer to the extent to which a particular regimen aims at inducing immunosuppression rather than myeloablation (as reviewed in 11)..
contains (or generates) immunocompetent cells, that the recipient is incapable of rejecting the graft, and that the host expresses tissue antigens that are foreign to the donor cells (3) . Today, donor immunocompetent T cells are generally accepted to be the effector cells of GvHD, as is evident from the preventive effects of exhaustive T cell depletion and the well-know correlation of GvHD severity with transplanted donor T cell dose (25,26). GvHD is considered as a three-step process in which innate and adaptive immunity interact. Firstly, the conditioning regimen causes damage to recipient tissues such as the intestinal wall, resulting in translocation of bacterial lipopolysaccharide (LPS) to the blood circulation, and activation of host antigen-presenting-cells (APC). Secondly, donor T cells interact "directly" with host (allo-) antigen expressed on host APC, resulting in activation, massive cytokine production and clonal expansion. Third, the "cytokine storm" and further T cell effector function, including cytotoxicity through perforin-and fas-mediated pathways, result in increasing host tissue damage (27). The immunobiology of chronic GvHD is less well understood. One theory postulates that chronic GvHD is a form of endstage alloreactivity in which an initial T helper (Th) 1 response evolves into a Th2-mediated process. Another theory holds that chronic GvHD results from a dysfunctional recovery of the immune system, as is thought to occur in what has been called 'autologous GvHD', the auto-immune syndrome that complicates cyclosporine administration after autologous HSCT (15).
Approaches to prevent or minimize the occurrence of GvHD include HLA matching, T cell depletion or T cell-suppressing pharmacotherapy. Although effective in the prevention of GvHD, T cell depletion is well known to be associated with increased risk of graft failure, infection, and malignant relapse (25). The standard pharmacologic GvHD prophylaxis mainly makes use of cyclosporine and methotrexate, either as monotherapy or in combination (28). Other immunosuppressants such as tacrolimus, CAMPATH, anti-thymocyte globulin and mycophenolate mofetil (MMF) have been used to prevent acute GvHD but evidence to their efficacy is limited, and they are therefore not considered standard therapy (29-32). The cornerstone in the treatment of established acute GvHD consists of high-dose corticosteroids (15) . For steroid-refractory acute GvHD, which is associated with poor prognosis, various strategies have been used, such as anti-TNF-alpha, anti-IL-2, anti-CD3 or anti-CD147 monoclonal antibodies (moAb)., extracorporeal photopheresis and the immunosuppressives pentostatin, rapamycin and MMF, but with limited success (33-38). Standard therapy for chronic GvHD consists of combination therapy with cyclosporine and prednisone (39) . In patients with steroid-refractory chronic GvHD, good results were recently reported with anti-CD20 moAb, and various other strategies have been reported on, such as PUVA, thalidomide, MMF and total lymphoid irradiation (40-46).
Graft-versus-leukemia effect
Since long, donor T lymphocytes are considered the principal GvL effector cells, but the ability of NK cells to also mediate antileukemic effects is increasingly being acknowledged (see section 3.3) (47). The target antigens for allogeneic GvL effector T lymphocytes include major histocompatibility (MHC) antigens, minor histocompatibility (miHC) antigens and tumor-associated antigens (TAA) ( Table 1 ) (48) . The importance of MHC and miHC antigens in GvL is illustrated by the close association between GvL and GvHD in recipients of alloHSC grafts. In 1990 already, Horowitz et al. (6) reported their observations that leukemia relapse was less frequent in patients who received alloHSCT and did not develop GvHD, than in patients who received syngeneic or T cell-depleted HSC grafts. The authors suggested the existence of a T cell-mediated GvL effect that selectively targets a subset of miHC antigens preferentially expressed on leukemic cells (and possibly also on normal hematopoietic cells) (6) . Today, 9 hematopoietic tissuerestricted miHC have been described: HA-1 (49), HA-2 (50), HA-8 (51), HB-1 (52), ACC-1 and ACC-2 (53), UGT2B17 (54), B8/H-Y (UTY) (55) , and LRH-1 (56) . MiHC are under consideration as potential targets for antitumor therapy because they are highly immunogenic, because miHC-specific T cell clones exhibit high avidity, thus increasing the likelihood of a response against tumor cells that express low levels of miHC antigens, and because miHC-specific T cell responses involve both CD4 + and CD8 + cells (reviewed in (57) Tumor-associated antigens are non-miHC selfantigens that are aberrantly expressed, either qualitatively or quantitatively, by tumor cells, and that can therefore be expected to elicit specific anti-tumor immune responses. TAAs can result either from mutation (e.g. bcr/abl mutation in CML), from overexpression (e.g. Wilms' tumor antigen 1), or from tissue-specific expression (e.g. prostate-specific antigen in prostate cancer, melanoma-associated antigen in testicular cancer) (48) . Most of the TAAs identified so far are non-mutated self-antigens that are differently expressed in the tumor and normal host tissue. Wilms' tumor antigen 1, myeloperoxidase (MPO), proteinase 3 (Pr-3), survivin, telomerase reverse transcriptase, CYPB1 and immature laminin receptor are examples of proteins that are expressed by leukemic cells at much higher levels than normal cells do, and that could therefore serve as targets for GvL (48) . Pr-3 is a serine protease that is maximally expressed at the promyelocyte stage of myeloid differentiation (62) and that is regulated by the transcription factors PU.1 and C/EBP-alpha, both of which have been implicated in leukemogenesis (63) (64) (65) . Myeloperoxidase is another myeloid-restricted protein and is expressed during early myeloid differentiation. Both MPO and Pr-3 are overexpressed in a variety of myeloid leukemia cells including approximately 75% of CML patients, 50% of AML patients and 30% of MDS patients. Evidence that Pr-3 and MPO can serve as target antigens for T cells originally stems from the observation that T cells, taken from patients with Wegener's granulomatosis or small vessel vasculitis, respectively, mount a proliferative response when stimulated with the particular antigen (66) . In patients with myeloid malignancies it has been demonstrated that CTLs directed against Pr-1 (which is an HLA-A2.1-restricted peptide derived from Pr-3), can lyse leukemic blasts (67) (68) (69) , and, furthermore, cytogenetic remission of CML following treatment with interferon-alpha has been described to correlate with the occurrence of these Pr-1-specific CTLs (70) . Finally, also Wilms' tumor antigen 1 is overexpressed in leukemic cells in AML, CML, ALL, MM and multiple solid tumors (71) (72) (73) (74) (75) , and evidence exists to indicate that anti-Wilm's tumor 1 CTLs can specifically lyse leukemic cells (76) (77) (78) .
STRATEGIES TO SEPARATE GRAFT-VERSUS-LEUKEMIA FROM GRAFT-VERSUS-HOST DISEASE
Since the first description of the concept of GvL, the emphasis in alloHSCT clinical practice and research lies on the immunotherapeutic capacity of the alloHSC graft rather than on the tumor-reducing effect of high-dose conditioning therapy. Key evolutions include the development of RIST regimens (Box 1), which aim to exploit GvL immune reactivity while reducing treatmentrelated toxicity and while controlling for GvHD, and the development of post-transplant immunotherapeutic approaches for the induction of GvL, most of which are based on DLIs. In addition, very recently it has become evident from human studies that NK cells can significantly contribute to GvL, and a potential therapeutic role for regulatory T cells (Treg) is emerging.
The conditioning regimen and the peri-transplant cytokine milieu
Originally, the purpose of the conditioning treatment before alloHSCT was to suppress the recipient's immune system and to eradicate the tumor, and it was therefore designed to be myeloablative. Current myeloablative conditioning regimens most commonly consist of a combination of cyclophosphamide and total body irradiation or busulphan (79) . However, it has become clear that even the most intensive regimen rarely eradicates the malignancy and that leukemic relapse relentlessly occurs if a GvL effect is not generated (80) (81) (82) . By comparing two regimens of high-dose irradiation, Clift et al. showed both in patients with AML in first remission (81) and in patients with CML in chronic phase (82) that an increase in the dose of total body irradiation failed to prevent leukemia relapse and to improve survival but resulted in increased mortality from causes other than disease recurrence. In order to minimize conditioningrelated toxicity, and thereby render older and frailer patients eligible for alloHSCT procedures, the RIST approach was developed. Through immunosuppression rather than myeloablation, so-called non-myeloablative protocols were designed to create immunological space in the bone marrow and lymphoid organs, so as allow for allogeneic engraftment (14) . The resulting, often low-level, mixed donor chimerism can subsequently be used as a platform for the induction or reinforcement of GvL through immunotherapeutic approaches such as DLI. Various regimens have been developed. Most common is the combination of fludarabine with other cytotoxic agents such as busulfan, cyclophopsphamide, melphalan, ATG, or with low-dose total body irradiation and post-transplant cyclosporine and MMF immunosuppressant treatment in the so-called 'mini-transplant' procedure (79) . In 1998, Slavin reported on 26 patients given alloHSCT with nonmyeloablative conditioning including fludarabine, anti-Tlymphocyte globulin, and low-dose busulfan. A good safety profile and strong antitumor responses were obtained (12). This study was followed by several reports on the efficacy of RIST in inducing donor chimerism and anti-tumor effects in patients with various types of haematological malignancies (9, 11) . A comparative study by Le Blanc et al. showed that the mini-transplant protocol, as compared to a standard non-myeloablative protocol, led to reduced risks for leucopenia and transfusion need, but increased incidences of graft failure, acute GvHD and transplantrelated mortality (83) .
Similar to what has been observed in myeloablative transplant regimens, anti-leukemic responses in RIST protocols have been shown to occur in association with progression from mixed to full donor chimerism, and often with the development of GvHD (84, 85) . It is well known that administration of cytotoxic or radiotoxic conditioning regimen results in the release of a range of inflammatory cytokines, and since long it has been accepted that this so-called 'cytokine storm' in the early post-transplant microenvironment crucially contributes to the pathophysiology of GvHD (86) . Chakraverty et al. recently showed in a mouse model that inflammation in nonlymphoid tissue is a prerequisite for migration of activated T cells to that site. Despite effective activation and expansion, adoptively transferred donor-type alloreactive T cells entered nonlymphoid tissues only in freshly irradiated mice and not in mixed chimeras (87). Similarly, as discussed below, abatement of the cytokine storm is thought to be one of the factors that account for the reduced risk for DLI-induced GvHD when DLI is administered several weeks or months rather than immediately after conditioning and transplantation; an observation that was made in the clinic and has been experimentally reproduced in mice (14, (88) (89) (90) (91) (92) . Hence, other than to limit direct organ toxicity, RIST may also have the beneficial consequence of reducing the risk for GvHD.
Randomized controlled trials comparing standard myeloablative conditioning with RIST are as yet not available. Uzunel et al. observed similar incidences of molecular remission in patients with CML following alloHSCT using RIST or myeloablative conditioning (93) . Also, Sorror et al. found that non-myeloablative conditioning before HLA-matched unrelated alloHSCT led to reduced risks for severe conditioning-related toxicity and severe GvHD (94) . In contrast, Mielcarek and coworkers reported that, rather than preventing GvHD, a nonmyeloablative regimen consisting of low-dose TBI and post-transplant cyclosporine and MMF altered the kinetics and tissue-specificity of GvHD, resulting in late-onset acute GvHD (after day 100 post transplantation) with skin being more frequently, and gut being more severely affected (95) . It is clear that RIST provides treatment opportunities for patients with advanced age, comorbidities or previous transplants. However, randomized controlled trials demonstrating its superior efficacy in inducing GVL without GvHD are as yet not available.
Hypothesizing that the peri-transplant cytokine environment can steer alloreactive T cells towards GvHD, investigators have studied the effect of various cytokines on GvHD and GvL reactivity in experimental alloBMT models, but few have been studied in a clinical context. Administration of anti-interleukin (IL)-1 moAb in a haplotype-mismatched murine alloBMT model resulted in reduced GvHD with preserved GvL effects (96) , but clinical studies on the effect of IL-1 inhibition on GvHD have yielded conflicting results. In an open-label, phase I/II trial in 17 patients with steroid-resistant GVHD, treatment with recombinant human IL-1 receptor-antagonist was found to be safe and to improve the severity of GvHD in 10 of 16 patients. However, in a double-blind, placebocontrolled randomized trial involving 186 patients, these results could not be confirmed (97, 98) . The observation that post alloHSCT GvHD was associated with high tumor necrosis factor alpha (TNF-alpha) serum levels (99) led to clinical studies evaluating the effect of anti-TNF-alpha moAb in the treatment of steroid-refractory GvHD. A multicenter pilot study in 19 such patients showed that infliximab was well tolerated but that it produced a partial response in a limited subset of patients only, and was generally ineffective in preventing GvHD recurrence (100) . Similarly, a retrospective study of 134 patients, treated with infliximab for steroid-resistant acute GvHD, showed a partial response, in particular in those with gastrointestinal involvement, but an increase in fungal and viral infections was noted (101) . Importantly, the observation in murine models that donor T cell-derived TNF-alpha is involved in the development of both GvHD and GvL suggest that TNFalpha blockade might abrogate GvL effects (96, 102, 103) , and data on the effect of TNF-alpha blockade on GvL in humans are as yet not available. Various other cytokines have been investigated for their role in GvHD and GvL. Administration of IFN-gamma, IL-2, IL-12 or IL-18 in variable models of experimental alloBMT was found to allow for a dissociation of GvL from GvHD (104-106). Also, administration of IL-11 in a murine model was shown to reduce CD4 + T cell-mediated GvHD without compromising the CD8 + T cell-mediated GVL effect. However, treatment of human transplant patients with IL-11 has been reported to result in serious adverse advents, and this has averted further clinical trials along this line (107) . Although these studies clearly demonstrate that interfering with the cytokine network may dissociate the GvHD and GvL effect, available evidence does not support a clear model that explains and unifies these phenomena, and this is probably due to our incomplete understanding of the cytokine network and the various cell populations involved. Furthermore, none of these studies have been translated into successful clinical trials.
Conventional bone marrow alloHSCT is being progressively replaced by peripheral blood alloHSCT. A recent meta-analysis has shown that peripheral blood alloHSCT is associated with enhanced GVL responses, and that -although also associated with an increase in severe acute GvHD and with an increase in chronic GvHD -it results in superior disease-free survival rates (108). In order to mobilize stem cells in the peripheral blood of alloHSC donors, granylocyte-colony stimulating factor (G-CSF) is commonly used, and recent studies have revealed how G-CSF pretreatment of donor cells can contribute to dissociated GvL and GvHD. The group of Morris, Macdonald and Hill et al. was able to show in murine models of mobilized peripheral blood alloHSCT, that G-CSF treatment of donor animals prior to transplantation can attenuate GvHD through effects on donor T cells (bias towards Th2 differerentiation and induction of Tr1 regulatory cells), and through effects on donor APCs (induction of regulatory APCs, immature myeloid precursors and plasmacytoid dendritic cells (DCs)), while these immune effects do not affect cytotoxic T cell function involved in GvL (109) (and as reviewed in (110)). They further showed that donor pretreatment with novel G-CSF analogs additionally results in expansion and activation of donor NK T cells, which upon transplantation critically contribute to superior GvL effects (111) (and as reviewed in (110).).
Targeting the T cell-mediated GvL effect
T cells are considered the principal effector cells of both GvH and GvL effects. The benefits of non-specific T cell-depletion, as a measure to prevent GvHD (25), is well known to be off-set by increased incidences of graft rejection, disease relapse and delayed immune reconstitution (112, 113) . Therefore, strategies have been developed that aim at exploiting the GvL reactivity of alloreactive T cells either through post alloHSCT adoptive transfer of donor T cells or subsets thereof, or through manipulation of the antigen-presenting cells with which they interact.
Interaction of GvH and GvL effector T cells with antigen-presenting cells
Both experimental and clinical data indicate that host-type APC play a key role in the generation of a GvL response after DLI (91, 92, 114) . Chimerism analysis in DLI-treated patients shows that responders generally become complete chimeras in conjunction with or before the GvL response, supporting the concept that the graftversus-hematopoietic-host response functions as a basis for the GvL effect (88, 114, 115) . This is supported by the observations in murine models that DLI yields stronger GvL effects in mixed as opposed to complete donor chimeras and that GvL is associated with T cell-mediated lymphohematopoietic GvH reactions establishing substantial increases in donor chimerism (91, 92) . Our group has shown in a mouse model of miHC-disparate alloBMT, that DLI yields stronger GvL effects in mixed than in complete donor chimeras and that DLI-induced GvL was associated with T cell-mediated lymphohematopoietic GvH reactions ( Figure 1 ) (92) . Using a model of class I-deficient beta-2-microglobulin knock-out BMT in recipient mice with normal MHC I expression, Mapara et al. showed that host APCs were required for DLI to induce GvH and GvL effects (91). Shlomchik et al. had previously delivered direct proof that elimination of host APCs after alloBMT led to abrogation of GvHD, but that this also had the undesired consequence of reducing GvL (116) . Other elegant mouse studies of alloBMT have subsequently confirmed that host-type APC are both crucial and sufficient for the development of GvHD (116) (117) (118) Reddy et al. who showed in a rodent model that alloantigen presentation by host APC present within the lymphohematopoietic system, and not by those residing within the GvHD target tissues, crucially determines the occurrence of a GvL response (120) . Furthermore, they found donor-derived APC only to contribute to the GvL effect through cross-priming of alloreactive CD8 + T cells in situations where the tumor burden had manifestly decreased (120) . These studies indicate that the selective depletion of APCs in GvHD target tissues, e.g. skin, while preserving them at other places such as secondary lymphoid organs where they would be required to initiate GvL, would represent a potential approach to separate GvL from GvHD, and Merad et al. recently demonstrated this approach to be effective in preventing murine GvHD (119) .
Another potential means to differentially interfere with the T cell -APC interaction involved in GvL and GvHD is to enhance DC presentation of leukemic antigens to effector T cells. Choudhury et (121, 122) . Similarly, it has been shown in mice that pretransplant vaccination of donor mice with recipient-type leukemic antigens potentiated post-transplant GvL without increased risk for GvHD (123) .
It is well known that, depending on DC subtype and maturation state, and on the type and duration of antigenic stimulus, the interaction between MHC/peptide complexes on the DC and T cells results either in tolerance or immune activation (124) 
Adoptive transfer of GvL effector T cells 4.2.2.1. Donor lymphocyte infusion
Early alloHSCT studies demonstrated that intensive conditioning regimens rarely eradicate hematological malignancies completely (81, 82) , and the practice of second alloHSCT (using HSC from another donor) in patients with post-transplant relapse was met with limited success due to high morbidity and mortality (127) . These observations led investigators to test whether infusion of lymphocytes, obtained from the original BM donor could be used as a means to induce post-transplant anti-leukemic immunoreactivity. The first reports on DLI in mice and humans were published by Slavin et al. in 1988 (7) . Today, the success of adoptive immunotherapy with DLI has provided the most compelling evidence that the GvL effect of allografts is crucial to the effectiveness of alloHSCT in the treatment for lymphohematopoietic malignancies, and has led to its routine application in clinical practice (128) (129) (130) . Although DLI has been applied in a wide range of hematological malignancies, considerable variability exists in the susceptibility of different types of leukemia to DLI-induced GvL (131) . CML is the most susceptible with responses being more frequent and durable for chronic-phase CML than for CML in blast crisis (132) . In other types of hematologic malignancies, e.g in AML, MM and MDS, responses are less frequent, and although a clear GvL reactivity for Philadelphia-chromosome-positive ALL has been noted, success in ALL is rare (128, (132) (133) (134) (135) (136) (137) (138) (139) (140) . The differential response of leukemia types to DLI is incompletely understood. Differences in growth kinetics (141, 142) , variable expression of co-stimulatory molecules (143) and differential ability of leukemic cells to differentiate into DC may play a role (121) . Indeed, the process of allogeneic engraftment and development of GvL may be outpaced by rapid proliferating aggressive malignancies such as AML, and GVL effector mechanisms may differ between leukemia types. Whereas it is established that T lymphocytes are extremely important in the generation of graft-versus-CML responses (144), the incidences of AML and ALL relapse have been shown to be less influenced by T cell-depletion (145) .
The effector mechanisms underlying the DLIinduced GvL effect are still incompletely understood but, as discussed earlier (section 3.1), studies in DLI-treated leukemia patients and in mouse models of alloHSCT have indicated graft-versus-lymphohematopoietic responses as the basis of the GvL effect. Childs et al. showed that DLItreated patients generally exhibit conversion from mixed to complete chimerism prior to, or at the time of the GvL response (114) . Moreover, marrow aplasia frequently complicates DLI in recipients who have insufficient donorderived normal progenitors (146) . Our studies in mice showed DLI to induce GvL and lymphohematopoietic GvH reactivity with expansion of host-reactive T cells only in mixed and not in complete donor chimeras (Figure 1) (92) . This was in accordance with a simultaneously published study in an MHC-mismatched model by Mapara et al., showing that host-type APC are required for the induction of potent DLI-induced GvH and GvL effects (91) . These studies therefore corroborate that also DLI-induced antileukemic reactivity is closely associated with broad anti-host reactivity, and therefore carries the risk for the development of GvHD. Also in the clinical setting, DLI does not fully separate GvL from GvHD. Studies by Collins et al. and Storb et al. showed that disease remission is related to the development of GvHD (131, 134) , and today, GvHD complicating DLI is still a major problem, occurring in approximately 50% of cases (8, 138) . Various DLI strategies have been experimentally and clinically explored in an attempt to optimize GvL while controlling for GvHD.
Timing of donor lymphocyte infusion
From clinical studies it became evident that DLI given early after HSCT led to high incidences of GvHD, whereas when postponed until several weeks or months after the transplant, DLI was associated with reduced GvHD rates. Furthermore, in those cases were GvHD did occur, it was generally mild and controllable (14, 90) . In accordance with these findings, experiments in murine models of alloBMT showed that DLI given immediately following BMT gave rise to acute GvHD, whereas when DLI was delayed for several weeks, GvHD was mild or even absent, while a potent GvL response could still be observed (92, (147) (148) (149) (150) . This was demonstrated by our group in a miHC-mismatched alloBMT model (Figure 2 ) (149). As suggested earlier, the higher susceptibility to GvHD in the early post-transplant period is thought to relate to overstimulation of effector donor T cells by the cytokine storm and local inflammation, unleashed by the conditioning regimen (86,87).
These studies of 'delayed' DLI in mice showed that GvHD could be avoided with preservation of GvL reactivity, and thus delivered proof of concept that DLI can induce GvL effects independently from GvHD. In humans also, the practice of giving DLI late after the initial transplant procedure, or with a non-myeloablative alloHSCT regimen designed to give less acute toxicity, has been shown to lead to significant anti-tumor responses with incidences of GvHD that were lower than one would expect when similar doses of donor T lymphocytes were infused at the time of myeloablative alloHSCT (see also section 3.1) (reviewed in (8)). Many studies have reported on efficacy and safety profiles of DLI regimens, the indication for DLI being either mixed chimerism, residual or relapsing disease without GVHD, or high-risk disease (9, 84, 132, 146, (151) (152) (153) (154) (155) (156) (157) (158) (159) (160) (161) (162) (163) . Bader et al. have shown that immunotherapy with prophylactic DLI drives the evolution of chimerism towards complete donor chimerism and leads to lower relapse rates (160) . This effect of pre-emptive DLI immunotherapy has been confirmed by others (8).
Dosing of donor lymphocyte infusions: multiple-dose and dose-escalating strategies
Clinical practice has not allowed to reliably define optimal DLI doses to obtain GvL effects. The lowest DLI dose capable of inducing fatal GvHD is on the same order of magnitude as the optimal dose required for the treatment of advanced leukemia (154, 138). Moreover, the minimal therapeutically effective DLI dose varies with the type of malignancy, CML requiring lower doses than MDS or ALL (154).
In a non-randomized clinical trial comparing single-dose with escalating-dose DLI to treat CML relapse, Dazzi et al. found that, despite similar cytogenetic remission rates, the 2-year incidence of GvHD was significantly lower in the escalating-dose DLI group than in the single-dose group, although both groups received comparable total lymphocyte doses (164) . Similarly, Peggs et al. and Mackinnon et al. used dose-escalating DLI protocols and found that GvL effects can be induced with DLI doses that are lower than those necessary to provoke GvHD (88,151,155,158) . The mechanism underlying the differential effect of repetitive DLI on GvL and GvH reactivity is not known. Repetitive infusion of non-tolerant donor lymphocytes might induce a regulatory circuit that differentially influences GvL and GvHD.
Composition of the donor lymphocyte inoculum 4.2.2.1.3.1. T cell subset donor lymphocyte infusion
The identification of the effector cells responsible for mediating GvL effects is a key question in alloHSCT research that remains incompletely answered. Studies in mouse models have delivered data to support a direct role for CD4 + , CD8 + T cells, or both, in DLI-induced GvL, but their relative contribution seems to vary between animal models and leukemia cell lines used (165) (166) (167) . Moreover, specific subsets have been identified that mediate both GvL and GvHD, and, hence, depletion of this particular subset resulted both in avoidance of GvHD-associated mortality and abrogation of GvL effect. Also in humans, both leukemia-specific CD4 + and CD8 + T cell lines have been described (168) (169) (170) (171) (172) , and patient studies on the effect of T cell-subset DLI are emerging (142, (173) (174) (175) (176) . In an early study, Champlin et al. found that CD8 + T cell-depleted alloHSCT gave rise to reduced GvHD, while GvL was preserved. However, this was at the expense of an increased incidence of graft failure (174) . Similarly, other have reported CD8
+ TCD DLIs to exert strong graft-versus-CML and graft-versus-myeloma effects, with reduced rates of severe acute GvHD (142, 173, 175, 176) .
Differential involvement of Th1 and Th2 cells in GvL and
GvH immune reactivity has been demonstrated in mouse models where adoptively transferred donor Th1 cells mediated a curative GvL effect and moderate GvHD, whereas Th2 cells mediated a variable GvL effect and caused only minimal GvHD (177,178).
Donor lymphocyte inocula depleted of alloreactive T cells
The depletion of alloreactive T cells from the DLI inoculum represents another possible approach to dissociate GvL from GvHD. Various techniques have been reported on, such as identification and elimination of alloreactive T cells based on the expression of activationinduced cell surface markers (such as CD25 and CD69). following in vitro stimulation in mixed lymphocyte culture. This approach has been reported to lead to abrogation of in vitro alloreactivity while leaving in vitro anti-viral or antitumor responses intact (179) (180) (181) (182) (183) (184) (185) . Amrolia and coauthors reported a phase I clinical trial, in which this approach resulted in low incidences of GvHD and infection.
However, effects on leukemic relapse remain to be established (186, 187 (191) . Furthermore, the authors established the feasibility of monitoring these clones in vivo in relation to GvHD and leukemia relapse. Although these findings provide a basis for a GvL approach that would be theoretically safe, the involvement of specific T cell clones probably varies between experimental and human leukemias. In addition, the identification, isolation and expansion of the relevant T cell clones is likely to be difficult. In analogy with the approach of depleting alloreactive T cells, Bachar-Lustig et al. demonstrated that, in mice, selective infusion of anti-third party T cells could induce a GvL effect without GvHD (192) . Similarly, Arditti et al., working with a humanized mouse model of B-CLL, showed that allogeneic, non-hostreactive anti-third-party CTL can establish a strong GvL response, while avoiding GvHD (193) .
Of note, it has recently been shown in mouse studies that the memory T cell subset of T cell inocula does not have the capacity to induce GvHD upon transfer in MHC-matched and MHC-mismatched allogeneic hosts (194, 195) , and that infusion of such T cell subsets allows for the transfer of specific memory (194 
DLI with suicide-gene transfected effector cells
GvH and GvL responses are thought to follow different kinetics after alloBMT and, consequently, differently timed interventions could result in separation of GvL from GvHD (197) . First and foremost, as mentioned above, both in mice and humans, delaying treatments with DLI for some time after the alloHSCT allows for GvL effects with reduced risk for GvHD (92) . Second, various methods of suicide gene-transfected T effector cell transfer have been used to demonstrate the feasibility of inducing dissociated GvL and GvH effects. GvL effects without GvHD have been obtained in mouse studies using herpes simplex virus thymidine kinase (HSV-Tk) gene-transfected donor T cells with timed administration of acyclovir (198) (199) (200) . So far, three patient studies have reported on the use of HSV-TK-transduced DLI, but described variable effects on anti-leukemic responses. Also, clinical application of this approach will need to address problems such as incomplete elimination of HSV-TK-transgene cells, and excessive elimination due to immunogenicity of the HSV-TK-transgene product (201) (202) (203) . Other suicide gene transfer-procedures have been developed in vitro and involve timed induction of a chimeric FAS protein (204) , the death effector domain (DED) of FADD (the human Fas-associated protein with death domain) (205) , or of caspase 8 (206).
Antigen-specific adoptive T cell therapy
Adoptive transfer of donor T cells specific for viral antigens has been shown to be effective and safe in the treatment of post-transplant CMV and EBV infection (207) . Candidate target antigens for antigen-specific adoptive T cell immunotherapy for hematologic malignancies include several miHC antigens and TAA. Marijt et al. reported a study in which 3 alloHSCT patients with relapsed HA-1-and/or HA-2-positive malignancies were treated with DLI form HA-1-and/or HA-2-negative donors. They found that all 3 patients achieved complete remission, with detectable levels of HA-1-and HA-2-specific CD8
+ cells, and thereby confirmed that these particular miHC-specific CTL can harness GvL in the clinic (61) . The observation that in donor-recipient pairs with an HA-1 and/or HA-2 mismatch in the GVH direction, up to 35% of the CTL clones generated after DLI were specific for HA-1 and HA-2 underlines the role of miHC antigens in GvL reactions (208) . However, clinically useful miHC antigens for anti-tumortherapy may not be confined to hematopoietic tissue restricted miHC antigens as So far, biologically relevant antigen-specific tumor responses against the known TAA have been difficult to document. It has been shown that CML cells can present peptides derived from the bcr/abl fusion protein (210) . Bcr/abl-derived peptide vaccinations have been shown to induce antigen-specific CD4 + T cell proliferative responses, but CD8 + T cell responses were not seen (211) . Similarly, in a transplanted CML patient, bcr/abl-specific CD4 + T cells were documented, but these failed to elicit cytotoxicity ex vivo (212, 213) .
Isolation and expansion of sufficient numbers of antigen-specific T cells has proved to be a technically demanding process, and hampers clinical applicability. Ex vivo expansion of leukemia-reactive CTLs is most promising in situations where the leukemic cells can be induced in vitro to differentiate into APCs, as has been shown for Philadelphia chromosome-positive CML, CLL and follicular lymphoma cells (121, 214, 215) . Alternatively, leukemia-reactive CTLs can be generated through TAAspecific TCR gene transfer, and successful attempts have been reported for both murine and human T cells. Human T cells transfected with the gene for WT1-specific T-cell receptor were shown to retain specificity and to be able to kill human leukemic cells (216) . However, in view of reports on malignant transformation of e.g. retroviral transfected human hematopoietic stem cells (217) , (pre)-<clinical development of this approach will need to address important safety issues (218) . Ongoing intensive research to identify new TAA and to unravel mechanisms of tumor immune recognition or immune escape will likely contribute to a further development of antigen-specific adoptive immunotherapy.
Recipient lymphocyte infusion
Although current alloHSCT strategies are designed to make use of the anti-leukemic effect of the graft and its derived cells, and although in vivo GvL effects are generally associated with donor-anti-host reactivity, strong anti-leukemic responses with sustained remissions have also been observed in patients that experienced loss of donor chimerism after a non-myeloablative stem cell transplant (219) . Moreover, in rodent studies, the group of Sykes et al. have documented that alloBMT followed by recipient lymphocyte infusion could also produce significant antileukemic effects, which was mainly mediated by IFN-gamma-producing recipient-type CD8 + and CD4 + T cells, and not by donor T cells (220, 221) . These observations suggest that not only donor-anti-host but also a host-anti-donor response can initiate and contribute to an anti-tumor response.
Targeting the NK cell-mediated GvL effect
The normal function of NK cells consists in recognizing and attacking virus-infected and malignantly transformed cells by non-antigen-specific mechanisms. However, clinical as well as experimental evidence indicates that NK cells can fulfil effector functions in GvH and GvL reactions associated with alloHSCT procedures. Activation of the NK cell depends on the balance between positive and negative signals transmitted through sets of stimulatory and inhibitory receptors for ligands on potential target cells (222, 223) . These receptors belong to different molecular classes: the killer cell immunoglobulin-like receptors (KIRs), the C-type lectins (NKG2 family) and the natural cytotoxicity receptors (NCRs). Triggering receptors are those that recognize ligands expressed by cells under stress (virus-infected and cancer cells). Inhibitory receptors recognize self MHC Class I molecules enabling NK cells to spare normal host cells while mounting their attack against prospective targets that miss these self MHC molecules (224). Of note, this 'missing self' theory does not explain all aspects of NK cell biology, since MHC class I expression is not in all instances sufficient to prevent NK cytotoxicity nor is it always a necessary condition (225) .
Each single inhibitory KIR recognizes antigenic determinants defining a group of 'self' MHC I alleles. For instance, in humans, the inhibitory KIR2DL2 and KIR2DL3 recognize group 1 HLA-C alleles (Cw1, Cw3, Cw7 and Cw8) having Ser77 and Asn80. In general, the inhibitory KIRs tend to have a greater affinity for their corresponding ligands than do the activating KIRs (226) . Thus diversity in KIR repertoire between individuals that are mismatched for subgroups HLA-C alleles establishes the basis for NK-cell mediated alloreactivity (Table 1) (47) .
The inhibitory C-type lectin receptors NKG2A, NKG2C, NKG2E, NKG2F are heterodimers containing a shared subunit (CD94) (227) . The activating NKG2D is a homodimer and may play a role in anti-tumor responses since its ligands are induced by neoplastic cell transformation. In humans, these ligands include two families, the MHC class I chain-related antigens (MIC) and the UL16-binding proteins (ULBPs) (228) (229) (230) . Besides NKG2D, other activating receptors without specificity for MHC class I molecules have been identified. Most of these seem to act as co-activators of NK cytotoxicity. In humans, these receptors are collectively called natural cytotoxicity receptors (NCRs) (231) (232) (233) (234) (235) . They are thought to be complementary to NKG2D in the MHC-independent recognition of tumor cells.
Evidence that NK cells can contribute to the GvL effect of BMT procedures stems from studies in patients undergoing MHC-mismatched haploidentical alloHSCT (47) . In this setting, the MHC Class I molecules of host cells may not correspond to the inhibitory receptors of the donor NK cell clones. In addition, leukemic cells may express ligands that trigger stimulatory NK cell receptors. Together, this may result in killing of host leukemic cells. NK cell alloreactivity is mainly limited to lymphohaematopoietic lineage cells, as epithelial cells are generally insensitive to NK cell-mediated killing, and this may result in engraftment while leaving clinical GvHD target organs (e.g. the gut) intact (223, 225) . MHCmismatched haploidentical alloHSCT is applied when an MHC-matched HSC donor is not available, and often involves multiple mismatches at MHC class I and II loci, a situation that is expected to result in severe GvHD. In order to prevent graft rejection and GvHD, such patients are given very intensive conditioning treatment and HSC grafts that are extensively depleted of T cells (236) . In several studies, the group of Martelli et al. have reported this approach to result in high rates of engraftment with low rate of severe GvHD (236) (237) (238) (239) . In addition to being the effect of preventive T cell depletion, the low rate of GvHD is thought to result from NK cell-mediated killing of hosttype APCs in GvHD target tissues. As mentioned earlier, these play a key role in eliciting GvHD (116) Exhaustive T cell depletion in this setting precludes significant T cell mediated GvL responses, and on the basis of studies in AML patients, Ruggeri et al. have reported data to indicate that in this setting, alloreactive NK cells contribute to GvL (240) . This has subsequently been confirmed by others for other types of haematological malignancies (241, 242) . Ruggeri et al (240) studied 57 high-risk AML patients given MHC-mismatched haploidentical HSCT. Twenty donor/recipient pairs showed a KIR epitope mismatch, with presence of donor-type alloreactive NK cells, whereas 37 pairs were KIR epitope compatible. In the patient group that received alloHSC with alloreactive NK cells, the five-year disease-free survival was 60%, as opposed to only 5% in the KIR ligandmatched group. Within the same study, such an effect of KIR epitope incompatibility could not be documented in ALL patients, and this is supported by the recent demonstration that NK cells fail to kill ALL cells in vitro (243) . Unfortunately, the results of KIR ligand incompatibility in recipients of alloHSCT are not unequivocal. This discrepancy remains unexplained but may be related to differences in patient populations, underlying diseases, conditioning regimens, graft composition, and post-transplant immunosuppressive regimens (244, 245) .
The role of regulatory cells in the dissociation of Graft-versus-host disease and Graft-versus-leukemia
Naturally occurring Treg were originally described as key regulators of autoreactive T cells (246, 247) . In addition to their role in maintaining tolerance to self, the role of Treg in transplantation tolerance is increasingly being acknowledged (248 (251) . In these settings, Treg did not influence engraftment, but instead facilitated multilineage hematopoietic reconstitution and the induction of donor chimerism. Importantly, subsequent studies showed that although Treg suppressed GvHD, they did not inhibit GvL effects (252, 253) . The potential of adoptively transferred Treg to obtain dissociated GvL and GvHD has led to the development of techniques to expand Treg and this has been successfully achieved for Treg in mice (254) . Human Treg have been successfully expanded but their in vivo regulatory role needs to be established (255) . The mode of action underlying the differential effect of Treg on GvHD versus GvL is as yet not understood. Possibly, Treg suppress the process of GvHD, which depends on indirect presentation of host antigens, at a time point when GVL reactivity has already taken place through a process of direct presentation (256) .
Total lymphoid irradiation (TLI) has been shown in mice to result in temporal non-specific immunosuppression and, when followed by reconstitution with MHC-mismatched BM, to lead to stable mixed chimerism without GvHD (257) (258) (259) (260) . Strober et al. found this protection from GvHD to depend on IL-4-producing host-type NK1.1 + T cells (259) , and recently, this group of investigators used NK T cell-deficient CD1 -/-mice to definitively show the critical involvement of NK T cells in attenuating GvHD (260) . Consistent with these findings, several murine studies have shown that administration of activating NK T cell ligands (e.g. glucocerebroside or alpha-galactosylceramide)., or treatment of donor lymphocytes with alpha-galactosylceramide (and IL-2) before adoptive transfer, results in an attenuation of GvHD (261) (262) (263) . Finally, as mentioned above, Morris et al. have documented the critical involvement of NK T cells in dissociated GVL and GvHD in models of G-CSF-analogmobilized peripheral blood alloHSCT (111) . With regard to the effect of TLI on GvL, Salam et al. found that TLI- treated mice exhibited superior GvL effects as compared to total body irradiation-conditioned mixed chimeras (258) . In support of this, it was recently shown that pre-transplant TLI and antithymocyte globulin-treatment in patients with malignant lymphoid diseases or acute leukemia lowered incidences of acute GvHD while GvL was preserved (264). Double-negative T cells were originally identified as a distinct immunoregulatory cell type, involved in tolerance induction after allo blood transfusion (265) . Recently, these cells were documented to be involved in regulating GvL without GvHD following single MHC I locus-mismatched lymphocyte infusion (266) . A role for double negative T cells in regulating alloreactivity has also been proposed in a murine model of miHC alloBMT and recipient lymphocyte infusion (267) .
CD11b
+ myeloid suppressor cells have been implicated to play a role in tumor-specific and tumor-nonspecific T cell dysfunction in carcinoma patients and in murine models of solid tumors (268) (269) (270) (271) (272) . Our group has shown that such cells transiently expand following myeloablation and murine miHC-disparate alloBMT ( Figure 3 ). As these CD11b + early myeloid cells were capable of IFN-gamma-induced nitric oxide-mediated suppression of alloreactive T cell responses ex vivo (not shown) we proposed a role for their involvement in dissociated GvL and GvH reactivity following DLI (273) .
Mesenchymal stem cells have anti-inflammatory and immunomodulatory effects. In particular, they have been shown to suppress alloreactive T cell responses while the cells themselves are poorly immunogenic (274, 275) (and reviewed in (276) ). A recent pilot study by Ringden et al (277) has demonstrated the potential of mesenchymal stem cells, obtained from a third-party individual, in attenuating GvHD, but the effect of this approach on GvL responses remains to be evaluated. In this study, third-party mesenchymal stem cell treatment was given to 8 patients with steroid-refractory grade III-IV acute GvHD: acute GvHD resolved completely in all 6 evaluable patients, and survival in the treated group was significantly better than that of similar patients not treated with mesenchymal stem cells (277).
4.5.
Biological, immunosuppressive and immunomodulatory agents
Agents of various kinds have been explored for a potential effect on GvHD and/or GvL. In most of these studies, the mechanism underlying differential immune effects was not explored in detail. It is well known that LPS and inflammatory cytokines play a key role in the initial events of GvHD (278) . Antagonisation of LPS, by the synthetic lipid-A analogue B975 resulted in attenuation of murine GvHD while GvL was preserved (278) . Furthermore, in mouse models of alloBMT, peri-transplant administration of the histone deacetylase inhibitor Suberoylanilide hydroxamic acid (SAHA) and the cytoprotective agent keratinocyte growth factor was found -through a repressive effect on the production of proinflammatory cytokines -to inhibit the inflammatory events leading to GvHD, while both CTL responses to host antigens and GvL reactivity were maintained (279, 280) . Similarly, administration of the metalloproteinase inhibitor KB-R7785, which inhibits release of TNF-alpha and FAS-L release, reduced GvHD while strong antitumor effects persisted (281) .
The proteasome inhibitor bortezomib, which is used in the treatment of myeloma, has been shown to inhibit alloreactive T cell responses in vitro, and, when timely administered in mouse alloBMT models, to segregate GvL from GvHD (282, 283) . Also, pre-treatment of DLI inocula with the lysosomotropic agent L-leucyl methyl ester, known to inhibit murine and canine GvHD through depletion of dipeptidyl peptidase I-expressing cytotoxic cellular subsets, has been demonstrated to lead to attenuated murine GvHD with preserved GvL (284).
Most immunosuppressive agents, such as FK506, rapamycin and deoxyspergualin, have been shown to inhibit both GvHD and GvL (285) (286) (287) , and although for some other agents such as MMF, FTY720 and the Janus kinase 3 inhibitor WHI-P131/JANEX-1 (288-291), differential effects on GvHD and GvL have been demonstrated, currently they are not clinically used to modulate GvHD and GvL. Using murine alloBMT models Schmaltz et al. have shown that donor T cells from TNF-related apoptosisinducing ligand (TRAIL)-deficient mice exhibited a weaker GvL effect than did those of wild-type mice, but possessed unaltered potential to induce GvHD (301) , suggesting that strategies to augment TRAIL-dependent antitumor reactivity might allow for dissociation of GvL and GvHD (302,303).
PERSPECTIVE
More than 2 decades of intensive clinical and experimental research on the therapeutic effects of alloHSCT for leukemias has allowed for major advances in the understanding of the immunobiology of GvL. Clinical and experimental strategies that induce GvL while controlling for GvHD have been developed, but the dissociation is rarely complete, and GvHD as well as leukemia relapse remain major causes of post-transplant morbidity and mortality. Strategies designed to exploit the well-known anti-leukemic properties of alloreactive donor T cells are DLI and RIST protocols. Although these have been shown clinically effective in eliciting GvL effects with reduced risks for GvHD, they will need to be further refined in order to achieve optimal GvL and, ultimately, eliminate the risk for GvHD. Antigen-specific adoptive T cell therapy theoretically would allow for a complete separation of anti-leukemic effects and broad anti-host reactivity. Although haematopoietic tissue-restricted miHC antigens are interesting candidate antigens, the required specific mismatches are not always present in selected donor-recipient combinations. The major challenge in this area is the identification of additional tumor-specific antigens, and the development of procedures that are not only technically adequate to isolate and expand antigenspecific T cells, but that are also clinically safe. The potential of alloreactive NK cells in mediating antileukemic effects on the basis of KIR-ligand mismatches is emerging. Although these NK cell-dependent GvL effects would require specific HLA allele mismatches, ongoing investigations of the immunobiology of NK cells and NK cell receptors may allow for the discovery of additional pathways of host-or leukemia-specific NK cell reactivity. Finally, potential future approaches to influence the balance between GvL and GvH reactivity of alloHSC grafts may rely upon the recently discovered naturally occurring Treg, which have been shown to differentially influence allo-and anti-leukemic reactivity in experimental models. 
